N@N

Arrayit Corporation: Arrayit Corporation Announces Worldwide Product Sales Up Nearly 50%

^{Published on 2009-07-23 04:16:22, Last Modified on 2009-07-23 04:16:29 - Market Wire}
 

SUNNYVALE, CA--(Marketwire - July 23, 2009) - Arrayit Corporation (OTCBB: [ ARYC ]), a proprietary life science technology leader, announces worldwide product sales up nearly 50% in the first half of 2009, to more than 3.1 million.

Arrayit microarray manufacturing technology has been the universal standard for printing and spotting microarrays since 1997. Arrayit leads and empowers the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure.

Over this past year Arrayit has continued to build and expand a sophisticated network of 38 international life science and diagnostics distributors, located in 36 countries. As a result, sales of Arrayit's advanced and innovative microarray contact printing technologies and instruments have exploded. To date, more than 10,000 customers worldwide possess the most sophisticated tools for research into diagnostics ever created, and Arrayit products are now found in more than 5,000 labs around the globe, where healthcare professionals, pharmaceutical companies, government laboratories, life science companies, academic institutions, biotechnology companies and hospitals are able to quickly and accurately identify specific diseases, pathogens and viruses in humans, animals or plants.

With Arrayit's diagnostic reading and printing systems in place, customers will now be positioned to better utilize many of the company's current and upcoming diagnostic screening platforms, which are expected to further boost sales revenues.

About Arrayit Corporation

Arrayit Corporation, headquartered in Sunnyvale, California, leads and empowers the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure. It now offers over 650 products to a customer base of more than 2,500 laboratories worldwide, including most every major university, pharmaceutical and biotech company, major agricultural and chemical company, government agency, national research foundation and many private sector enterprises. Please visit [ www.arrayit.com ] for more information.

Safe Harbor Statement

Except for historical information contained herein, statements made in this release that constitute forward-looking statements are based on currently available information, involve certain risks and uncertainties and the Company assumes no responsibility to update any such forward-looking statement. The following factors, among others, may cause actual results to differ materially from the results suggested in the forward-looking statements. Risks that may result from changes in the Company's business operations; our ability to keep pace with technological advances; significant competition in the biomedical business; our relationships with key suppliers and customers; quality and consumer acceptance of newly introduced products; market volatility; non-availability of product; excess inventory; price and product competition; new product introductions, the outcome of our legal disputes; the possibility that the review of our prior filings by the SEC may result in changes to our financial statements; and the possibility that stockholders or regulatory authorities may initiate proceedings against Arrayit and/or our officers and directors as a result of any restatements. Risk factors associated with our business, including some of the facts set forth herein, are detailed in the Company's Form 10-K/A for the fiscal year ended December 31, 2008 and Form 10-Q/A for the fiscal first quarter ended March 31, 2009 and Form 10-Q/A for the fiscal third quarter ended September 30, 2008.